Review of Operations continued EXOSOME DIAGNOSTICS The Exosome Ovarian Cancer Screening test (EXO-OC™ test) is a next-generation, exosomebased blood test in development for screening ovarian cancer in asymptomatic, average-risk women. EXO-OC uses proprietary EXO-NET® technology to isolate exosomes and combines multiple exosomal biomarkers in an AIenhanced algorithm to enable the early and accurate detection of ovarian cancer. Currently, there is no approved screening test to detect ovarian cancer early when treatment can be more effective and patient outcomes and survival improved. During the year, INOVIQ and the University of Queensland conducted a retrospective, blinded, case-control study to evaluate the performance of EXO-OC test in age-matched ovarian cancers (Stage I-IV), benign masses and healthy controls. Exosomes were isolated from blood samples using EXO-NET® on a fully-automated high-throughput robotic platform. The analysis was completed in two stages with the exosomal protein biomarkers measured using targeted mass spectrometry and miRNA biomarkers using RNA sequencing, and their diagnostic performance was confirmed using AI-enhanced machine learning modelling and ROC curve analysis. › On 3 December 2024, INOVIQ announced that its blood test for ovarian cancer screening had successfully completed an independent validation of its protein biomarkers and diagnostic performance, delivering accuracy of over 94% with sensitivity of 92% for all stages at a specificity of 96%, and 91% detection of Stage I alone. RESEARCH & DEVELOPMENT (R&D) PROGRESS INOVIQ pipeline products have the potential to deliver significant clinical and commercial benefits to patients, health systems and shareholders. R&D activities during FY25 focused on advancing the exosome program across our diagnostics and therapeutics pipeline, as well as adding to the SubB2M diagnostics data package. 10 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3